Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Hypoglycemia01:26

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Advancements of artificial intelligence in dry eye].

[Zhonghua yan ke za zhi] Chinese journal of ophthalmology·2025
Same author

Oral Functions and Various Cooking Methods Associated With Chewing-To-Swallowing Time in Community-Dwelling Older Adults.

Journal of oral rehabilitation·2025
Same author

[Progress in diagnosis and treatment of liver damage in endocrine diseases].

Zhonghua nei ke za zhi·2024
Same author

[Evaluation of thermal environment and human thermal comfort in 8 types of public places from 2019 to 2021].

Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases·2023
Same author

[Efficacy of a recombinant bovine basic fibroblast growth factor gel for the treatment of moderate dry eye: a multicenter randomized double-blind parallel controlled clinical trial].

[Zhonghua yan ke za zhi] Chinese journal of ophthalmology·2021
Same author

Pressure induced superconductivity in MnSe.

Nature communications·2021
Same journal

Correction: How Exercise Affects Exerkines in Metabolic Syndrome.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme·2026
Same journal

Impact of Vitamin D Replacement on the Vitamin D-Leptin-Prolidase Axis in Secondary Hyperparathyroidism.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme·2026
Same journal

Determinants of Infant Participation and Non-Participation in Primary Prevention Trials.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme·2026
Same journal

Inflammatory Profile of Lipedema: A Comparative Evaluation with Obese and Normal-weight Women.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme·2026
Same journal

Comparative Effects of Experimental Diabetes Mellitus and Glucocorticoid-Induced Hypercortisolemia on Pancreatic and Adrenal Endocrine Architecture: A Pathological Study in Rats.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme·2026
Same journal

Psychiatric Symptoms in Women with Mild Autonomous Cortisol Secretion Versus Non-Functioning Adrenal Adenomas: A Cross-Sectional Study.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme·2026
See all related articles

Related Experiment Video

Updated: May 9, 2026

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway
08:15

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway

Published on: May 10, 2024

Decrease of hyperglycemia by syringaldehyde in diabetic rats.

S C Kuo1, H H Chung2, C H Huang3

  • 1Department of Ophthalmology, Chi-Mei Medical Center, Yong Kang, Tainan City, Taiwan.

Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme
|August 7, 2013
PubMed
Summary
This summary is machine-generated.

Syringaldehyde effectively lowers postprandial glucose in diabetic rats without affecting insulin levels. It improves glucose utilization, potentially through reduced PEPCK expression and increased GLUT 4 in muscle.

Related Experiment Videos

Last Updated: May 9, 2026

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway
08:15

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway

Published on: May 10, 2024

Area of Science:

  • Pharmacology
  • Endocrinology
  • Metabolic Research

Background:

  • Syringaldehyde, derived from Hibiscus taiwanensis, is recognized for its potential to reduce hyperglycemia.
  • The precise mechanisms underlying syringaldehyde's glucose-lowering effects have not been fully elucidated.
  • Understanding these mechanisms is crucial for developing novel anti-diabetic therapies.

Purpose of the Study:

  • To investigate the glucose-lowering mechanisms of syringaldehyde in type 1-like (streptozotocin-induced) and type 2-like (fructose-fed) diabetic rat models.
  • To assess the impact of syringaldehyde on postprandial glucose levels, insulin sensitivity, and key gene expressions related to glucose homeostasis.

Main Methods:

  • Induction of diabetes in rats using streptozotocin (STZ) or a fructose-rich diet.
  • Administration of syringaldehyde and assessment via postprandial glucose tests.
  • Hyperinsulinemic euglycemic clamp studies to evaluate insulin sensitivity.
  • Analysis of gene expression for phosphoenolpyruvate carboxykinase (PEPCK) in the liver and glucose transporter subtype 4 (GLUT 4) in skeletal muscle.

Main Results:

  • Syringaldehyde significantly reduced postprandial plasma glucose levels in diabetic rats, with no observed effect on plasma insulin.
  • The glucose infusion rate (GIR), a measure of insulin sensitivity, was markedly improved in fructose-fed rats treated with syringaldehyde.
  • Repeated syringaldehyde administration in STZ-diabetic rats led to decreased hepatic PEPCK expression and increased skeletal muscle GLUT 4 expression.

Conclusions:

  • Syringaldehyde demonstrates efficacy in lowering hyperglycemia in diabetic rat models.
  • The compound appears to enhance glucose utilization, potentially by modulating key enzymes and transporters involved in glucose metabolism.
  • These findings suggest syringaldehyde as a promising candidate for further investigation as an anti-diabetic agent.